冠心苏合丸的药理研究及其简化制剂—苏冰滴丸的理论基础

用小鼠耐缺氧试验和麻醉狗冠状窦血流量(CSF)及心脏动-静脉血氧差(MA-VO₂)的实验研究冠心苏合丸及其成分的作用,发现:(1)冠心苏合丸能延长小鼠耐缺氧的时间;(2)冠心苏合丸能使心肌梗塞狗的CSF回升,减少心率和MA-VO₂,对非心肌梗塞狗不能提高CSF但亦能减少心率和MA-VO₂;(3)在本实验条件下,苏合香脂和冰片似为冠心苏合丸中起作用的两个成分,其余成分如檀香、青木香、乳香或其油均未能证实其效果。根据此理论,已制成一种新型制剂苏冰滴丸,治心绞痛有效。

SOME PHARMACOLOGIC EFFECTS OF THE "STYRAX PILL FOR CORONARY DISEASE" AND THE PHARMACOLOGICAL BASIS OF A SIMPLIFIED STYRAX-BORNEOL PREPARATION

Prior administration of "Styrax Pill for Coronary Disease" proper (6 components viz., styrax liquidus, Borneolum, Lignum santali, Aristolochia, Olibanum and Cinnabaris) or the mixture of Styrax liquidus, Borneolum, Lignum Santali and Olibanum to mice prolonged the survival time of the animals subjected to low pressure hypoxia. Styrax liquidus and Borneolum administered separately showed the same effect, whereas none of the other four components showed significant protection.A model of acute myocardial infarction was prepared by ligation of the left coronary anterior descending artery (LAD) in 24 dogs. Measurements of coronary sinus blood flow (CSF, ml/min), heart rate(HR), carotid artery blood pressure (BP, mmHg) and difference of oxygen contents between arterial and coronary sinus blood flow (MA-VO₂, Vol%) were made during the preligation control period, postligation ischemic period and one hour after treatment. Most of the LAD-ligated dogs showed progressive decreases of arterial blood pressure and CSF, accompanied by a somewhat persistent tachycardia and widening of the gradient between oxygen levels of arterial and sinus blood, that is, an increase of MA-VO₂ resulted. Treatment with "Styrax Pill for Coronary Disease" slowed the HR (average —37±5 beats/min), made CSF recover partially or completely (average +3.4 ±1.7 ml/min) and MA-VO₂ decreased (average—5.7±2.3 Vol%), but BP was maintained at the same level as the postligation period. Similar effects on HR, CSF and MA-VO₂ were produced by Styrax liquidus and Borneolum while Lignum santali, Aristolochia and Olibanum were ineffective.It appears that Styrax liquidus and Borneolum are the two active compositions which reproduce the cardiovascular actions of the "Styrax pill for Coronary Disease", while the other four components are ineffective. As a result of this study a new preparation composed of Styrax liquidus and Borneolum is now available for treating angina pectoris and is used clinically with promising results.